Tvardi Competitors
| TVRD Stock | 4.06 0.25 5.80% |
Tvardi Therapeutics vs FibroGen Correlation
Moving against Tvardi Stock
| 0.54 | TARS | Tarsus Pharmaceuticals | PairCorr |
| 0.39 | JAZZ | Jazz Pharmaceuticals PLC | PairCorr |
| 0.34 | MIST | Milestone Pharmaceuticals | PairCorr |
| 0.31 | AZN | AstraZeneca PLC ADR | PairCorr |
Tvardi Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Tvardi Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Tvardi and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Tvardi Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Tvardi Stock performing well and Tvardi Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tvardi Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CALC | 5.44 | (0.14) | 0.00 | 0.38 | 0.00 | 12.74 | 40.42 | |||
| LTRN | 3.47 | (0.27) | 0.00 | (0.07) | 0.00 | 10.27 | 23.91 | |||
| LVTX | 1.32 | 0.30 | 0.00 | 1.29 | 0.00 | 6.25 | 11.10 | |||
| ATNM | 3.02 | (0.14) | 0.00 | (0.13) | 0.00 | 5.84 | 20.75 | |||
| ELUT | 4.65 | 0.47 | 0.06 | (0.45) | 4.97 | 9.52 | 33.48 | |||
| PDSB | 3.97 | (0.02) | 0.01 | 0.05 | 4.61 | 8.60 | 27.78 | |||
| RVPH | 5.78 | (0.81) | 0.00 | (1.09) | 0.00 | 10.71 | 57.05 | |||
| XLO | 2.18 | (0.42) | 0.00 | (0.74) | 0.00 | 4.23 | 15.41 | |||
| TPST | 4.69 | (1.58) | 0.00 | (1.62) | 0.00 | 7.92 | 57.69 | |||
| FGEN | 2.67 | (0.19) | 0.00 | 0.49 | 0.00 | 4.33 | 28.75 |
Cross Equities Net Income Analysis
Compare Tvardi Therapeutics and related stocks such as CalciMedica Common Stock, Lantern Pharma, and LAVA Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CALC | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (37 M) | (27.5 M) | (35.8 M) | (7.8 M) | (34.4 M) | (13.7 M) | (15.8 M) | (16.5 M) |
| LTRN | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (2.4 M) | (5.9 M) | (12.4 M) | (14.3 M) | (16 M) | (20.8 M) | (18.7 M) | (17.8 M) |
| ELUT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.9 M) | (21.8 M) | (24.8 M) | (32.9 M) | (37.7 M) | (53.9 M) | (48.6 M) | (46.1 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
| TPST | (2.7 M) | (2.7 M) | (13.5 M) | (29 M) | (49.5 M) | (73.2 M) | (82.3 M) | (84.6 M) | (27.2 M) | (44.6 M) | (19.1 M) | (28.3 M) | (35.7 M) | (29.5 M) | (41.8 M) | (37.7 M) | (39.5 M) |
Tvardi Therapeutics and related stocks such as CalciMedica Common Stock, Lantern Pharma, and LAVA Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Tvardi Therapeutics financial statement analysis. It represents the amount of money remaining after all of Tvardi Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Tvardi Therapeutics Competitive Analysis
The better you understand Tvardi Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Tvardi Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Tvardi Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Tvardi Therapeutics Competition Performance Charts
Five steps to successful analysis of Tvardi Therapeutics Competition
Tvardi Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Tvardi Therapeutics in relation to its competition. Tvardi Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Tvardi Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Tvardi Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Tvardi Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Tvardi Therapeutics position
In addition to having Tvardi Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Tvardi Therapeutics Correlation with its peers. For information on how to trade Tvardi Stock refer to our How to Trade Tvardi Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Pharmaceuticals sector continue expanding? Could Tvardi diversify its offerings? Factors like these will boost the valuation of Tvardi Therapeutics. If investors know Tvardi will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Tvardi Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.25) |
Understanding Tvardi Therapeutics requires distinguishing between market price and book value, where the latter reflects Tvardi's accounting equity. The concept of intrinsic value—what Tvardi Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Tvardi Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tvardi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tvardi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tvardi Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.